Q/C Technologies, Inc. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
Q/C Technologies, Inc. (QCLS) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $2.18 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2026-04-15
- Q/C Technologies, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Q/C Technologies, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Q/C Technologies, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-12-31 was $325.00.
- Q/C Technologies, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-09-30 was $551.00.
- Q/C Technologies, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2025 was $2.18K, a 122.95% increase from fiscal 2024.
- Q/C Technologies, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was $976.00, a 134.62% increase from fiscal 2023.
- Q/C Technologies, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was $416.00.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $0.00 derived: sum of 2 quarters · filed 2026-04-15 | $2.18K 10-K · filed 2026-04-15 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $2.18K 10-Q · filed 2025-11-19 | ||
| 2025-06-30 | $2.18K 10-Q · filed 2025-08-19 | |||
| 2024-12-31 | $325.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $876.00 derived: sum of 2 quarters · filed 2026-04-15 | $801.00 derived: sum of 3 quarters · filed 2026-04-15 | $976.00 10-K · filed 2026-04-15 |
| 2024-09-30 | $551.00 10-Q · filed 2025-11-19 | $476.00 derived: sum of 2 quarters · filed 2025-11-19 | $651.00 10-Q · filed 2025-11-19 | |
| 2024-06-30 | -$75.00 10-Q · filed 2025-08-19 | $100.00 10-Q · filed 2025-08-19 | ||
| 2023-12-31 | $416.00 10-K · filed 2025-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |